Flemingsberg Science Foundation at Almedalen

We at the foundation have spent a sunny week in Almedalen 2024. It was a week filled with many insights and exciting discussions, and a highlight for us was our roundtable discussion, which we organized together with Huddinge Municipality. There, we delved into Flemingsberg’s significance for southern Stockholm as a world-leading player in life science. Pernilla Boström, COO of the Flemingsberg Science Foundation, shares more.

“It was very inspiring to lead and participate in the roundtable discussion we organized together with Huddinge Municipality about Flemingsberg’s significance for southern Stockholm as a world-leading player in life science. Sharing insights and experiences with a group of wise individuals from different perspectives was extremely rewarding.”

“I left Almedalen tired and satisfied, with many new impressions. I have had the privilege to participate, contribute, and be inspired alongside colleagues and partners. It has been a bustling exchange of knowledge, opportunities to influence and make a difference, and generous conversations and meetings – both formal and informal. The days were long, but I am already looking forward to next year’s Almedalen Week.”

The purpose of the roundtable discussion was to raise awareness about Flemingsberg’s development in life science and create a platform for the exchange of experiences. We shared valuable insights on how Flemingsberg can become one of Sweden’s most significant centers for education, research, and creativity. A discussion that we hope will continue even after Almedalen.

Watch our film with interviews and a summary of the discussion.

Cellaviva: improving lives through stem cell technology

“Cellaviva was founded by researchers from Karolinska Institutet, in the belief that stem cells will revolutionize how complex and incurable diseases are treated. We are a biobank that helps expectant parents to save stem cells from the umbilical cord at birth, in a so-called family bank. The aim is to make high-quality, potent cells available quickly, if medical needs arise. This creates treatment opportunities and expands therapy options for the whole family,”

NextCell to treat type 1 diabetes in children with stem cells

NextCell Pharma in Flemingsberg has published extremely promising results from its clinical studies of drug candidate ProTrans for the treatment of type 1 diabetes. A study is now being carried out with the aim of examining its efficacy in children and young people.

Go to Top